Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

CATALINA-2: een fase 2-studie van TORL-1-23 bij gevorderde eierstokkanker.

16 november 2026 bijgewerkt door: TORL Biotherapeutics, LLC

Catalina-2: een fase 2-studie ter evaluatie van de werkzaamheid en veiligheid van TORL-1-23 bij vrouwen met gevorderde platina-resistente epitheliale ovariumkanker (inclusief primaire peritoneale en eileiderkankers) waarbij Claudin tot expressie komt 6

A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

230

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Melbourne
      • Clayton, Melbourne, Australië, VIC 3168
        • Monash Medical Centre
    • New South Wales
      • Blacktown, New South Wales, Australië, 2148
        • Blacktown Hospital
    • Queensland
      • Chermside, Queensland, Australië, QLD 4032
        • Icon Cancer Centre Chermside
    • South Australia
      • Bedford Park, South Australia, Australië, 5042
        • Flinders Medical Centre
    • Western Australia
      • Perth, Western Australia, Australië, WA 6009
        • Linear Clinical Research
    • Antwerp
      • Edegem, Antwerp, België, 2650
        • Antwerp University Hospital (UZA)
    • Brussels Capital
      • Woluwe-Saint-Lambert, Brussels Capital, België, 1200
        • Cliniques Universitaires Saint-Luc
    • Flemish Brabant
      • Leuven, Flemish Brabant, België, 3000
        • UZ Leuven
    • Wallonia
      • Liège, Wallonia, België, B-4000
        • CHU Liège
    • British Columbia
      • Abbotsford British Columbia, British Columbia, Canada, V2S 0C2
        • BC Cancer - Abbotsford
      • Vancouver, British Columbia, Canada, V5Z 4E6
        • British Columbia Cancer Agency (BC Cancer, part of the Provincial Health Services Authority)
    • Ontario
      • Toronto, Ontario, Canada, M4N 3M5
        • Sunnybrook Research Institute
      • Toronto, Ontario, Canada, M5G 2M9
        • Princess Margaret Cancer Centre - University Health Network (UHN)
    • Quebec
      • Montreal, Quebec, Canada, H3T 1E2
        • Sir Mortimer B. Davis Jewish General Hospital
      • Montreal, Quebec, Canada, H1T 2M4
        • Hospital Maisonneuve Rosemont
      • Montreal, Quebec, Canada, H2X 0C2
        • Centre Hospitalier de l'Universite de Montreal (CHUM)
      • Montreal, Quebec, Canada, H4A 3J1
        • McGill University Health Centre (MUHC) - Royal Victoria Hospital
    • Baden-Wurttenberg
      • Heidelberg, Baden-Wurttenberg, Duitsland, 69120
        • Universitatsklinikum Heidelberg
    • Bavaria
      • Erlangen, Bavaria, Duitsland, 91054
        • Universitätsklinikum Erlangen
    • Free and Hanseatic City of Hamburg
      • Hamburg, Free and Hanseatic City of Hamburg, Duitsland, 20246
        • Universitätsklinikum Hamburg-Eppendorf, Clinic for Gynecology
    • State of Berlin
      • Berlin, State of Berlin, Duitsland, 13353
        • Charité Universitätsmedizin Berlin
    • Auvergne- Rhôn-Alpes
      • Lyon, Auvergne- Rhôn-Alpes, Frankrijk, 69008
        • Centre Leon Berard
    • Pays de la Loire Region
      • Saint-Herblain, Pays de la Loire Region, Frankrijk, 44805
        • Institut de Cancérologie de l'Ouest
    • Île-de-France Region
      • Villejuif, Île-de-France Region, Frankrijk, 94805
        • Institut Gustave Roussy
    • Connacht
      • Galway, Connacht, Ierland, H91YR71
        • University Hospital Galway
    • Leinster
      • Dublin, Leinster, Ierland, D07 R2WY
        • Start Dublin - Mater Misericordiae University Hospital
      • Dublin, Leinster, Ierland, DO8C9X2
        • St. James Hospital
    • Apulia
      • Bari, Apulia, Italië, 70124
        • IRCCS Giovani Paolo II - Instituto Oncologico
    • Milano
      • Milan, Milano, Italië, 20159
        • Humanitas San Pio X
    • Prato
      • Prato, Prato, Italië, 59100
        • Nuovo Ospedale di Prato S Stefano
    • Rome
      • Rome, Rome, Italië, 00168
        • Fondazione Policlinico Universitario A. Gemelli IRCCS
    • Styria
      • Graz, Styria, Oostenrijk, 8036
        • Medizinische Universitat Landeskrankenhaus Graz
    • Tyrol
      • Innsbruck, Tyrol, Oostenrijk, 6020
        • Universitatsklinik Innsbruck
    • Upper Austria
      • Linz, Upper Austria, Oostenrijk, 4010
        • Ordensklinikum Linz
    • Singapore
      • Singapore, Singapore, Singapore, 119074
        • National University Cancer Institute
      • Singapore, Singapore, Singapore, 168583
        • National Cancer Centre
      • Singapore, Singapore, Singapore, 217562
        • Curie Oncology (Farrer)
    • Catalonia
      • Girona, Catalonia, Spanje, 17007
        • Institut Catalá d'Oncologia de Girona
    • Madrid
      • Madrid, Madrid, Spanje, 28034
        • Hospital Universitario Ramón y Cajal
      • Madrid, Madrid, Spanje, 28006
        • Hospital Clinico San Carlos
    • Moravian-Silesian
      • Nový Jičín, Moravian-Silesian, Tsjechië, 74101
        • Hospital Agel, Nový Jičín
      • Ostrava, Moravian-Silesian, Tsjechië, 708 52
        • University Hospital Ostrava
    • Prague
      • Libeň, Prague, Tsjechië, 180 81
        • Fakultni Nemocnice Bulovka Gynekologicko-Porodinická Klinika
      • Prague, Prague, Tsjechië, 120 00
        • Vesobecna Fakultni Nemocnice Klinika Gynekologie, Porodnictvi a Neonatologie
    • Arizona
      • Phoenix, Arizona, Verenigde Staten, 85054
        • Mayo Clinic Hospital
      • Tucson, Arizona, Verenigde Staten, 85711
        • TMC HealthCare
    • California
      • Duarte, California, Verenigde Staten, 91010
        • City of Hope National Medical Center
      • Fullerton, California, Verenigde Staten, 92835
        • Providence St. Jude Medical Center
      • Los Angeles, California, Verenigde Staten, 90095
        • UCLA - JCCC Clinical Research Unit
      • Palo Alto, California, Verenigde Staten, 94304
        • Stanford Cancer Center
      • Santa Barbara, California, Verenigde Staten, 93105
        • SCRI - Sansum Clinic
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80045
        • University of Colorado Hospital - Anschutz Cancer Pavilion
    • Connecticut
      • New Haven, Connecticut, Verenigde Staten, 06510
        • Smilow Cancer Hospital at Yale - New Haven
    • Florida
      • Jacksonville, Florida, Verenigde Staten, 32224
        • Mayo Clinic Florida
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30322
        • Winship Cancer Institute, Emory University
    • Illinois
      • Chicago, Illinois, Verenigde Staten, 60637
        • University of Chicago Medical Center
    • Maryland
      • Annapolis, Maryland, Verenigde Staten, 21401
        • SCRI - Maryland Oncology Hematology, P.A.
    • Massachusetts
      • Boston, Massachusetts, Verenigde Staten, 02114
        • Massachusetts General Hospital
    • Minnesota
      • Minneapolis, Minnesota, Verenigde Staten, 55404
        • University of Minnesota
      • Minneapolis, Minnesota, Verenigde Staten, 55404
        • SCRI - Minnesota Oncology Hematology, P.A.
      • Rochester, Minnesota, Verenigde Staten, 55905
        • Mayo Clinic
    • Missouri
      • St Louis, Missouri, Verenigde Staten, 63108
        • Washington University
    • New Jersey
      • New Brunswick, New Jersey, Verenigde Staten, 08901
        • Rutgers Cancer Institute
    • North Carolina
      • Durham, North Carolina, Verenigde Staten, 27710
        • Duke Cancer Center
    • Ohio
      • Columbus, Ohio, Verenigde Staten, 43210
        • The James Cancer Hospital and Solove Research Institute - Ohio State University
    • Oklahoma
      • Oklahoma City, Oklahoma, Verenigde Staten, 73104
        • Stephenson Cancer Center at the University of Oklahoma
    • Oregon
      • Portland, Oregon, Verenigde Staten, 97227
        • SCRI - Northwest Cancer Specialists, P.C.
    • Pennsylvania
      • Doylestown, Pennsylvania, Verenigde Staten, 18901
        • SCRI - Alliance Cancer Specialists, PC
      • Philadelphia, Pennsylvania, Verenigde Staten, 19104-4238
        • University of Pennsylvania
    • Tennessee
      • Germantown, Tennessee, Verenigde Staten, 38138
        • The West Clinic, PLLC dba West Cancer Center
    • Texas
      • Dallas, Texas, Verenigde Staten, 75390
        • University of Texas Southwestern Medical Center
      • Fort Worth, Texas, Verenigde Staten, 76104
        • SCRI - Texas Oncology
    • Virginia
      • Norfolk, Virginia, Verenigde Staten, 23502
        • SCRI - Virginia Oncology Associates
    • Washington
      • Seattle, Washington, Verenigde Staten, 98104
        • Providence Swedish Cancer Institute
    • Gangnam-Gu
      • Seoul, Gangnam-Gu, Zuid -Korea, 06351
        • Samsung Medical Center
    • Gwanak-gu
      • Seoul, Gwanak-gu, Zuid -Korea, 03080
        • Seoul National University Hospital
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Zuid -Korea, 10408
        • National Cancer Center
      • Seongnam-si, Gyeonggi-do, Zuid -Korea, 14396
        • CHA University Bundang Medical Center
    • Seocho-Gu
      • Seoul, Seocho-Gu, Zuid -Korea, 06591
        • The Catholic University of Korea, Seoul St. Mary's Hospital
    • Seodaemun-Gu
      • Seoul, Seodaemun-Gu, Zuid -Korea, 03722
        • Yonsei University Health System, Severance Hospital
    • Songpa-Gu
      • Seoul, Songpa-Gu, Zuid -Korea, 05505
        • Asan Medical Center

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Vrouw

Beschrijving

Inclusion Criteria:

Participants are eligible to be included in the study only if all the following criteria apply:

  1. Females ≥18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the informed consent.

  2. Participants must sign the informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

  3. Disease Type:

    • Histologically or cytologically confirmed diagnosis of advanced (unresectable) or metastatic high grade serous ovarian, primary peritoneal (i.e, of primary origin), or fallopian tube cancer. High-grade endometrioid ovarian cancer is permitted for enrollment.
    • Participant's tumor must be positive for CLDN6 expression as defined by the CLDN6 reference laboratory assay. Tumor tissue will be required for submission for CLDN6 testing prior to Cycle 1 Day 1.
    • Participants must have platinum-resistant disease, defined as the following:
    • If participants received only 1 line of platinum-based therapy, they must have completed 4 or more cycles of platinum-containing therapy, must have achieved a CR or PR, and progressed >3 months but ≤6 months after the last dose of platinum.
    • Participants who have received more than 1 line of platinum- based therapy must have progressed on or within 6 months after the last dose of platinum.
    • NOTE: This should be calculated from the date of the last administered dose of platinum therapy to the date of the radiographic imaging showing progression (per RECIST v1.1).
    • Participants who are platinum-refractory during front-line treatment are excluded.
    • Participants must have received at least 1 but no more than 3 prior systemic lines of anticancer therapy, and for whom single- agent therapy is appropriate as the next line of treatment. Study rules for evaluation of number of prior systemic lines of therapy:
    • Adjuvant ± neoadjuvant is considered one line of therapy
    • Maintenance therapy (eg, bevacizumab or PARP inhibitors) will be considered part of the preceding line of therapy (ie, not counted independently)
    • Therapy changed due to toxicity in the absence of progression will be considered part of the same line (ie, not counted independently)
    • Hormonal therapy will not be counted as a separate line of therapy
  4. Measurable disease, per RECIST v1.1

  5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.

  6. Adequate organ function, based on the following laboratory values:

    • ANC: ≥1,500/mcL

    • Platelets: ≥100,000/mcL without transfusion within 4 weeks of first dose

    • Hemoglobin: 9 g/dL with transfusion or EPO support up to 14 days before eligibility assessment

    • Measured or calculated creatinine clearance with a validated formula*: ≥30 mL/min

    • Serum total bilirubin: ≤1.5 X ULN (participants with known Gilbert disease or liver metastases who have serum bilirubin level ≤3×ULN may be enrolled

    • AST (SGOT) and ALT (SGPT): ≤3 X ULN (participants with active liver metastases who have ALT/AST ≤5 X ULN may be enrolled)

    • Albumin: ≥2.5 g/dL

    • ECG: 12-Lead ECG with normal tracing or non-clinically significant changes that do not require medical intervention and QTcF interval

      • 470 msec and without history of Torsades des Pointes or other symptomatic QTc abnormality.
  7. Participants of childbearing potential must have a negative serum pregnancy test within 72 hours before starting study drug treatment. The serum pregnancy test must be negative for the participant to be eligible.

  8. Participants must agree to use a highly effective birth control method from the time of the first study drug treatment through 7 months after the last study drug treatment, or be of nonchildbearing potential.

  9. Participants must agree not to donate eggs from the first study drug treatment through 7 months after the last study drug treatment.

  10. Participants must agree to not breastfeed from the first dose of study treatment through 90 days after the last dose of study treatment.

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  1. Has not recovered [recovery is defined as National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0, Grade ≤1] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.

  2. Participants with clear cell, mucinous, sarcomatous (including carcinosarcoma), mixed histology, or low-grade, borderline ovarian tumors or non-epithelial ovarian cancers.

  3. Participants with primary platinum-refractory ovarian, primary peritoneal (i.e. of primary origin) or fallopian tube cancer, defined as disease that did not respond to or has progressed within 3 months of the last dose of first line platinum-containing chemotherapy.

  4. Received prior chemotherapeutic, investigational, radiotherapy, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-1-23. There is no waiting period required for stereotactic radiosurgery.

  5. Prior treatment with a CLDN6-targeting agent or an MMAE-containing ADC.

  6. Progressive or symptomatic brain metastases. Brain metastases that have been radiated, are asymptomatic, and on a stable or decreasing dose of steroids are allowed. Leptomeningeal disease is excluded.

  7. Grade 2 or greater peripheral neuropathy.

  8. History of non-infectious pneumonitis/ILD within 6 months of first dose of study drug.

  9. Participants must not be considered a high medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent.

  10. History of significant cardiac disease:

    1. Congestive heart failure >New York Heart Association class 2 within last year
    2. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months)
    3. Myocardial infarction less than 6 months before start of study drug
    4. Anti-arrhythmic therapy (beta blockers are permitted)
    5. Any unstable ischemic disease or untreated arrhythmia
  11. Known history of myelodysplastic syndrome or acute myeloid leukemia.

  12. History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. Participants with malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ of the breast are not excluded.

  13. Uncontrolled infection; active, clinically serious infections (CTCAE Grade >2).

  14. Participants with seizure disorder requiring medication.

  15. Known hypersensitivity or intolerance to any of the study drugs, study drug classes, or excipients in the formulation.

  16. History of having an allogeneic bone marrow or organ transplant.

  17. Any condition (concurrent disease, infection, or comorbidity) that interferes with ability to participate in the study, causes undue risk, or complicates the interpretation of safety data, in the opinion of the Investigator.

  18. Participants who are taking any drugs that are strong inducers and/or strong inhibitors of CYP3A4 enzymes.

  19. Participants who are taking any drugs that are inhibitors of P-glycoprotein.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Cohort 1

Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.

2.4mg/kg intravenous infusion on Day 1 of every 3-week cycle.

3.0 mg/kg intravenous infusion on Day 1 of every 3-week cycle.

3.4 mg/kg intravenous infusion on Day 1 of every 3-week cycle.

6.0 mg subcutaneous injection on Day 4 of each cycle.

Experimenteel: Cohort 2

Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.

2.4mg/kg intravenous infusion on Day 1 of every 3-week cycle.

3.0 mg/kg intravenous infusion on Day 1 of every 3-week cycle.

3.4 mg/kg intravenous infusion on Day 1 of every 3-week cycle.

6.0 mg subcutaneous injection on Day 4 of each cycle.

Experimenteel: Cohort 3

Participants will receive TORL-1-23 on Day 1 of each 21-day cycle. Additionally, pegfilgrastim will be administered on Day 4 of each 21-day cycle.

2.4mg/kg intravenous infusion on Day 1 of every 3-week cycle.

3.0 mg/kg intravenous infusion on Day 1 of every 3-week cycle.

3.4 mg/kg intravenous infusion on Day 1 of every 3-week cycle.

6.0 mg subcutaneous injection on Day 4 of each cycle.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
To assess the efficacy of TORL-1-23 as a monotherapy in women with advanced PROC expressing CLDN6
Tijdsspanne: At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months

Objective Response Rate (ORR) per RECIST v1.1 by Blinded Independent Central Review (BICR)

At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Duration of Response (DOR)
Tijdsspanne: At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months

To assess additional efficacy outcome measures of TORL-1-23 per RECIST v1.1 by Blinded Independent Central Review (BICR) and investigator assessment

At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months
Objective Response Rate (ORR)
Tijdsspanne: At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months

To assess additional efficacy outcome measures of TORL-1-23 per RECIST v1.1 by investigator assessment

At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months
Progression-free Survival (PFS)
Tijdsspanne: At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months

To assess additional efficacy outcome measures of TORL-1-23 per RECIST v1.1 by Blinded Independent Central Review (BICR) and by investigator assessment

At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months
Overall Survival (OS)
Tijdsspanne: From time of consent until death or completion of study (Study duration is approximately 40 months)

To assess additional efficacy outcome measures of TORL-1-23

From time of consent until death or completion of study (Study duration is approximately 40 months)
Incidence and severity of AEs and clinical laboratory abnormalities per CTCAE v5.0
Tijdsspanne: From informed consent until 30 days after the last dose of study treatment, approximately 24 months (each cycle is 21 days)

To assess the safety and tolerability of TORL-1-23

From informed consent until 30 days after the last dose of study treatment, approximately 24 months (each cycle is 21 days)
CA-125 response per Gynecological Cancer Intergroup (GCIG) criteria
Tijdsspanne: At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months

To assess the pharmacodynamic effects of TORL-1-23

At predefined intervals from Dose 1 until documented disease progression, total overall study duration approximately 40 months

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

20 november 2024

Primaire voltooiing (Geschat)

1 oktober 2027

Studie voltooiing (Geschat)

1 december 2027

Studieregistratiedata

Eerst ingediend

13 november 2024

Eerst ingediend dat voldeed aan de QC-criteria

13 november 2024

Eerst geplaatst (Werkelijk)

15 november 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

16 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

ONBESLIST

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Ja

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren